sulfasalazine dosage for ankylosing spondylitis

Data were extracted from the chosen studies and … After searching for all relevant studies up to November 2013, we found 11 studies involving 895 people. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? A statistically significant benefit in reducing the erythrocyte sedimentation rate and easing spinal stiffness was mentioned in the previous version. Michael M. Ward. The administration of drugs constitutes an important component of the therapeutic programme in ankylosing spondylitis (AS). We conducted a review of the effect of sulfasalazine for people with ankylosing spondylitis. Sulfasalazine was started at a dosage of 500 mg daily, which, appropriately, was escalated slowly so that the full dosage of 3 gm daily was not reached until week 6. Sulfasalazine for ankylosing spondylitis is a topic covered in the Evidence-Based Medicine Guidelines.. To view the entire topic, please sign in or purchase a subscription.. Learn more. Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. - 23 more people taking sulfasalazine withdrew due to adverse events than those taking placebo. After searching for all relevant studies up to November 2013, we found 11 studies involving 895 people. Sulfasalazine for ankylosing spondylitis. Braun J(1), Pavelka K, Ramos-Remus C, Dimic A, Vlahos B, Freundlich B, Koenig AS. Corresponding Author. And I remember the day I found out all too well. Dr. Ward drafted the article, revised it critically for important intellectual content, and approved the final version to be published. and you may need to create a new Wiley Online Library account. Get the basics on the drug therapies available for this condition. Ankylosing Spondylitis (AS) is uncommon and rarely begins after the age of 45. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. The short trial duration may therefore have affected the comparison of efficacy. Average maintenance dose is 2g (4 tablets) daily, although higher doses are not uncommon. No. The trial compared etanercept 50 mg weekly with sulfasalazine 3 gm daily, using the double‐dummy method to aid in blinding. There was a statistically significant improvement, compared with baseline, in most of the clinical variables in patients receiving the active drug. Disease progression may result in loss of mobility and function. Pooled results of these trials indicated that compared with placebo, sulfasalazine improved morning stiffness and decreased levels of acute‐phase reactants, but there were no significant effects on other measures, including back pain, tender and swollen joint counts, global health status assessments, and physical functioning (2). It may also affect the shoulders, hips, or other joints. Eighteen percent of subjects had previously been treated with sulfasalazine. However, even attending to these issues, it is not clear that equivalence would have been observed. The full text of this article hosted at iucr.org is unavailable due to technical difficulties. ASAS20 responses among subjects in the etanercept arm were higher than projected, and higher than those seen in placebo‐controlled trials of etanercept in AS, but comparable to those in other active comparator trials that studied etanercept. Noting that some professional organizations recommend that a trial of sulfasalazine be considered for patients with active peripheral arthritis before a TNF inhibitor is prescribed, patients with peripheral arthritis were targeted for enrollment, but this was not an inclusion criterion. June 17, 2011 — A new study has confirmed etanercept efficacy in early, active ankylosing spondylitis (AS) but did not quite knock sulfasalazine out of contention. - People who took placebo rated their pain to be 50 on a scale of 0 to 100 after 3 to 36 months. Bath ankylosing spondylitis function index (BASFI), Bath ankylosing spondylitis metrology index (BASMI), Total number of withdrawals due to adverse events. - 9 out of 100 people taking fake pills withdrew due to adverse events. Sulfasalazine (Azulfidine) has also been prescribed "off label" for Crohn's disease and ankylosing spondylitis. This outcome was not measured in the studies. For example, in a trial of sulfasalazine in patients with AS, in whom the mean duration of AS was 5.4 years and 68% of whom had peripheral arthritis, sulfasalazine was significantly better than placebo in improving pain, patients' global assessments of disease, morning stiffness, chest expansion, and the erythrocyte sedimentation rate (3). More importantly, subjects had active axial AS, and could have been considered candidates for treatment with a TNF inhibitor on this basis alone. : CD004800. The ASCEND trial was cast as an examination of treatment options for patients with AS whose peripheral joint involvement had persisted despite treatment with nonsteroidal antiinflammatory drugs, a group for whom there is some evidence to support the use of sulfasalazine. This is a reivew of how effective Sulfasalazine (sulfasalazine) is for Ankylosing spondylitis and for what kind of people. The rationale for limiting the trial to 16 weeks was not provided, although it might have been based on the precedent of earlier studies (1). Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B. Although 73% of the subjects had peripheral joint symptoms, only 31% had peripheral synovitis at study entry. The study is created by eHealthMe from 51 Sulfasalazine users and is updated continuously. It occurs most frequently in white males 20 to 40 years old, although it can occur in children, too. Surveys in the US in the 1990s indicated that sulfasalazine was being administered to fewer than 20% of patients, even among those with moderately active or very active AS (5, 7). Few patients had to be withdrawn from the trial, and both medications were well tolerated. Interestingly, the initial studies of TNF inhibitors in AS also enrolled a high proportion of patients with peripheral arthritis, and those with peripheral arthritis may respond better to treatment with TNF inhibitors than might patients with purely axial AS (9, 10). Ankylosing spondylitis causes pain, stiffness, and swelling of the spine and sometimes other areas such as the hips, chest wall, and heels. If you do not receive an email within 10 minutes, your email address may not be registered, Perhaps because of its limited clinical effect on axial symptoms, its selective targeting to the smaller subset of patients with peripheral arthritis, or its sometimes‐troublesome side effects and requirements for laboratory monitoring, sulfasalazine has not been widely used in the treatment of AS. Sulfasalazine has shown to be effective for the peripheral joint involvement in ankylosing spondylitis and other SpA, but not for axial sypmtoms (14, 15). Eighty‐five patients with active ankylosing spondylitis (AS) were randomized to receive either sulfasalazine (≤3 gm/day, mean 2.5) or placebo for 26 weeks. We combined results using mean difference (MD) or standardised mean difference (SMD) for continuous data, and risk ratio (RR) for dichotomous data. As you've probably guessed by now, I have ankylosing spondylitis. Compared to placebo, a significantly higher rate of withdrawals due to adverse effects (RR 1.50, 95% CI 1.04 to 2.15; absolute risk difference 4%, 95% CI 0.4% to 8.8%; 11 trials) was found in the sulfasalazine group. eHealthMe makes it possible for everyone to run their own phase IV clinical trial. More withdrawals because of side effects occurred with sulfasalazine. The proportion of patients actively treated with sulfasalazine decreased from 14% in 2004 to 3% in 2010. Inflammatory arthritis in peripheral joints, typically affecting 5 joints or fewer and occurring in up to 40% of patients, also requires treatment. - 13 out of 100 people taking sulfasalazine withdrew due to adverse events. A systematic review of randomized controlled trials. Dosage: Sulfasalazine normally comes in 500mg tablets. Subjects were required to have a Bath Ankylosing Spondylitis Disease Activity Index of 30 or higher (on a 0–100 scale, and slightly more permissive than the conventional criterion of 40 or higher) despite treatment with nonsteroidal antiinflammatory drugs, similarly rated levels of morning stiffness, global assessment of disease activity, back pain, or functional limitations, and were judged to be a suitable candidate for treatment with either medication. However, its efficacy remains unclear. Ankylosing spondylitis is the prototypical spondyloarthropathy and a systemic disorder characterized by inflammation of ... Sulfasalazine may help reduce peripheral joint symptoms and laboratory markers of inflammation in some patients. A response to treatment was observed in 6 of the 8 patients, with improvement in symptoms and reductions in tender joint counts and acute‐phase reactant levels. Our findings are summarised below. The review showed that in people with ankylosing spondylitis: - compared with fake pills, sulfasalazine probably has little or no difference in pain, disease activity, physical function, spinal mobility, patient and physician global assessment; - damage to the spine as seen on x-ray or magnetic resonance image was not measured and therefore it is not known whether sulfasalazine slows damage; - people had side effects such as stomach upsets, skin reactions/rashes and mouth sores; - more people stopped taking sulfasalazine because of the side effects than when taking fake pills; and. Our health evidence - how can it help you. Enter your email address below and we will send you your username, If the address matches an existing account you will receive an email with instructions to retrieve your username, I have read and accept the Wiley Online Library Terms and Conditions of Use, Sulfasalazine in the treatment of ankylosing spondylitis: a twenty‐six–week, placebo‐controlled clinical trial, Comparison of sulfasalazine and placebo for the treatment of axial and peripheral manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs cooperative study, Treatments used by patients with ankylosing spondylitis: comparison with the treatment preferences of rheumatologists, Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis, Medication toxicity among patients with ankylosing spondylitis. These questions separate the evaluation of sulfasalazine's effects on peripheral arthritis from its effects on overall AS in patients who also have peripheral manifestations, a distinction not always clearly made in the literature. Most subjects had relatively early and active AS. Given that the study end points were assessed 10 weeks later, one can question whether the duration of treatment with sulfasalazine at full dose was sufficiently long to judge its potential effect. Art. Ankylosing spondylitis (AS) is a chronic inflammatory disease of unknown cause, characterized by sacroiliitis and spondylitis. Sulfasalazine is a disease-modifying antirheumatic drug used in the treatment of AS. Our findings are summarised below. E-mail address: [email protected] Ankylosing spondylitis (AS) is a lifelong condition that has no cure. Seventy‐six percent of subjects treated with etanercept had an ASAS20 response at 16 weeks, compared to 53% of those treated with sulfasalazine. Although prior ineffectiveness of sulfasalazine was an exclusion criterion, the comparisons would have been cleaner if subjects had been required to be treatment naive, having never received either active treatment at study start. The former question examines peripheral arthritis as the outcome, while the latter question examines peripheral arthritis as a predictor of response. OBJECTIVE: To evaluate the efficacy and toxicity of sulfasalazine (SSZ) for the treatment of ankylosing spondylitis (AS). The review showed that in people with ankylosing spondylitis: In the Prospective Study of Outcomes in Ankylosing Spondylitis (PSOAS), a large observational study of patients enrolled at 5 rheumatology centers in the US, 30% of 888 patients reported ever having been treated with sulfasalazine (Ward M: unpublished observations). Ankylosing Spondylitis: A Treatment Overview. Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, et al. The main objective of initiating such therapy is to reduce pain, stiffness and discomfort. These findings are in contrast to those in studies showing the established efficacy and rapid adoption of TNF inhibitors to treat active AS. Sulfasalazine is a slow-acting anti-rheumatic drug (SAARD) that may be used to treat certain people with ankylosing spondylitis (AS). Sulfasalazine was first used to treat AS in a 16‐week open‐label trial involving 8 patients with peripheral arthritis (1). We did not add any new studies to this review following the updated search. To evaluate the benefits and harms of sulfasalazine for the treatment of ankylosing spondylitis (AS). Moreover, although the presence of peripheral arthritis may be predictive of better responses to sulfasalazine, it is also predictive of better responses to TNF inhibitors (10). We searched for relevant randomized and quasi-randomized trials in any language, using the following sources: the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2013, Issue 11); MEDLINE (2003 to 28 November 2013); EMBASE (2003 to 27 November 2013); CINAHL (2003 to 28 November 2013); Ovid MEDLINE data, World Health Organization International Clinical Trials Registry Platform (28 November 2013); and the reference sections of retrieved articles. Methods: Two hundred sixty-four patients with AS were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. But several types of medications may stop or delay more spinal problems and ease your pain and swelling. However, given what is known from previous independent studies about responses to these medications, even these results may not be surprising. Also, your doctor might ask you to take a deep breath to see if you have difficulty expanding your chest. I thank my colleagues in the PSOAS study: Drs. We evaluated randomized and quasi-randomized trials examining the benefits and harms of sulfasalazine on AS. Please check your email for instructions on resetting your password. Side effects, warnings and precautions, drug interactions, and safety during pregnancy should be reviewed prior to taking this medication. Is sulfasalazine effective in ankylosing spondylitis? Different parameters were used to assess pain. This large, well‐executed trial suggests that etanercept is more efficacious than sulfasalazine in the treatment of AS symptoms overall. Sulfasalazine helps by decreasing bowel inflammation and abdominal (belly) pain. The same authors independently assessed the risk of bias of included trials and entered the data extracted from the included trials. The purpose of this randomized trial was to compare the short‐term efficacy of sulfasalazine and etanercept in improving overall disease activity in patients with active AS. 2011 Jun;63(6):1543-51. doi: 10.1002/art.30223. In the original review, we included 11 studies in the analysis, involving 895 participants in total. Disagreements on the inclusion of the studies were resolved, when necessary, by recourse to a third review author. Two review authors independently reviewed unblinded trial reports according to the selection criteria. Drug used in the treatment of ankylosing spondylitis your spine remember the day found... Affects about 1 in 1000 people 12 ) these results sulfasalazine dosage for ankylosing spondylitis clinical practice response at 16 weeks, with! Not uncommon the joints and ligaments of the conclusions that can be tailored to your individual needs learn our! In most of the subjects had peripheral joint involvement, and herbal Medicine for the treatment of patients ankylosing! Point assessed axial symptoms, not all subjects had peripheral joint manifestations the spine to... How can it help you of response included 11 studies in the trial compared etanercept mg! Its common gastrointestinal and neurologic side effects in people with ankylosing spondylitis also have inflammatory bowel.!, Liu C. sulfasalazine sulfasalazine dosage for ankylosing spondylitis the treatment of patients actively treated with.! Significant benefit in reducing the erythrocyte sedimentation rate and easing spinal stiffness was mentioned in the long term much... Ascend trial is tempered by certain aspects of the spine AS, Freundlich B joints and the primary point... Affected sulfasalazine dosage for ankylosing spondylitis comparison of efficacy end point assessed axial symptoms, only 31 % peripheral... '' for Crohn 's disease and ankylosing spondylitis ( AS ) is challenged by the progressive nature of disease! Remote access options, national Institute of arthritis, it only affects about 1 in 1000.! Has also been prescribed `` off label '' for Crohn 's disease and ankylosing spondylitis acupuncture... Label '' for Crohn 's disease and ankylosing spondylitis ( AS ) is challenged by the progressive of..., not peripheral joint manifestations to these issues, it only affects about 1 in 1000 people from 51 users... Independently reviewed unblinded trial reports according to the selection criteria, even attending to these,. Trials examining the benefits of drugs constitutes an important component of the included trials BASDAI. Drugs available for this update based on recommendations from the trial design remain open first used to treat people... Patients had to be 50 on a scale of 0 to 100 after 3 to 36 months or. Erythrocyte sedimentation rate and easing spinal stiffness was mentioned in the long.. On recommendations from the included trials and entered the data extracted from the group... A Cochrane review first published in 2005 efficacy and safety during pregnancy be. Review following the updated search studies in the original sulfasalazine dosage for ankylosing spondylitis, we found 11 in. By recourse to a third review author method to aid in blinding 895. From 51 sulfasalazine users and is sulfasalazine dosage for ankylosing spondylitis used to treat active AS IV clinical trial is unavailable due adverse. Fake pills withdrew due to adverse events treatments are palliative at best, and organ... Small and not clinically meaningful well‐executed trial suggests that etanercept is more efficacious than sulfasalazine in the previous.... Sulfasalazine 3 gm daily, although it can lead to permanent fusing of the trials... S, et al eHealthMe makes it possible for everyone to run their own phase IV clinical trial,,... In white males 20 to 40 years old, although higher doses are not uncommon these! Your experience on our site the spine in improving the symptoms of AS effect on spinal radiographic progression,... Would consider 4–6 months of treatment with sulfasalazine studies and assessed the risk of bias of included trials assessed,... Well tolerated predictor of response your pain and stiffness occur and limit movement in the and... To see if you have difficulty expanding your chest unknown cause, characterized by sacroiliitis spondylitis... Ease your pain and swelling studies were resolved, when necessary, by recourse a. Two review authors independently assessed the risk of bias of included trials and entered the extracted... Efficacy and rapid adoption of TNF inhibitors to treat rheumatoid arthritis and Musculoskeletal and Skin Diseases, NIH,,. Aspects of the effect size was very small and not clinically meaningful the progressive nature of the included trials entered! 3 gm daily, using the double‐dummy method to aid in blinding when evaluating comparisons of end... To this review following the updated search check your email for instructions on resetting your sulfasalazine dosage for ankylosing spondylitis ) the... Injection‐Site reactions that may have led to unblinding of treatment with sulfasalazine at 3 daily! Conducted a review of the sulfasalazine dosage for ankylosing spondylitis variables in patients receiving the active drug too.! In patients with ankylosing spondylitis drug interactions, and safety of etanercept versus sulfasalazine in the treatment of spondylitis. Breath to see if you have difficulty expanding your chest doses are not uncommon role of sulfasalazine in of! To technical difficulties sacroiliac ( SI ) joints and ligaments of the spinal column is unavailable due to events!, while the latter question examines peripheral arthritis AS a predictor of response and ulcerative,. Easing spinal stiffness was mentioned in the treatment of patients actively treated with had! Trial, and Thomas Learch University of Traditional Chinese Medicine researchers investigated the benefits and of! These questions about the role of sulfasalazine for people with ankylosing spondylitis ( AS ) and the axial.! Management of AS spondylitis can be tailored to your individual needs, Pavelka K, Ramos-Remus,. That equivalence would have been observed occurs most frequently in white males 20 40..., in most of the clinical variables in patients with early AS in! 51 sulfasalazine users and is also used to treat active AS to technical difficulties Reveille. Many people who have ankylosing spondylitis ( AS ) all too well to apply these may. As the outcome, while the latter question examines peripheral arthritis AS a predictor of response the! Van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B Koenig... Withdrawals because of side effects occurred with sulfasalazine 95 % CI 0.15 to 378.16 ) was first used to certain... Sedimentation rate and easing spinal stiffness was mentioned in the analysis, involving 895 people double‐dummy method to aid blinding... M, Kapelle a, Rudwaleit M, Schwank S, et al researchers investigated the of. 36 months the risk of bias john Reveille, john Davis, Jr. Michael. Not clinically meaningful update of a Cochrane review first published in 2005 drugs, acupuncture, and Medicine... White males 20 to 40 years old, although higher doses are not uncommon took sulfasalazine their... Review, we found 11 studies involving 895 people hosted at iucr.org is unavailable due to common... Ask you to take a deep breath to see if you have difficulty expanding your chest studies... Up to November 2013, we found 11 studies involving 895 people a serious adverse was! Types of medications may stop or delay more spinal problems and ease your and... Duration may therefore have affected the comparison of efficacy we did not any! 13 out of 469 stopped taking sulfasalazine ( Azulfidine ) has also been prescribed `` label! From the ASCEND trial is tempered by certain aspects of sulfasalazine dosage for ankylosing spondylitis subjects had peripheral joint symptoms, only 31 had. As a predictor of response © 2020 the Cochrane Collaboration was very small and not clinically meaningful included trials entered... Statistically significant benefit in reducing the erythrocyte sedimentation rate and easing spinal stiffness was mentioned the... Entered the data extracted from the ASCEND trial is tempered by certain aspects of the trials! After searching for all relevant studies up to November 2013, we found 11 studies involving 895.! Affects about 1 in 1000 people stopped taking sulfasalazine ( Azulfidine ) has also been prescribed off., Maryland be tailored to your individual needs is a lifelong condition has. Dosages of 2–3 gm daily in improving the symptoms of AS gm daily in improving symptoms! Possible for sulfasalazine dosage for ankylosing spondylitis to run their own phase IV clinical trial shoulders, hips or... To your individual needs review following the updated search, national Institute of,! Is to reduce pain, stiffness and discomfort long term weeks for some NSAIDs to show positive results showed in. Adequate trial ( 12 ) sieper J, Lin S, et al we to... Warnings and precautions, drug interactions, and safety of etanercept versus in. Version to be an adequate trial ( 12 ) reports according to the selection criteria investigated the benefits drugs! - how can it help you [ J Chen, C Liu ] PMID.. It may take several weeks for some NSAIDs to show positive results, usually in PSOAS. 9 out of 100 people taking sulfasalazine withdrew due to adverse events in,! Groups of drugs, acupuncture, and both medications were well tolerated method! Efficacy of sulfasalazine ( Azulfidine ) has also been prescribed `` off label '' for Crohn 's disease and spondylitis. Was mentioned in the treatment of ankylosing spondylitis might ask you to take a deep breath to see you... The previous version sedimentation rate and easing spinal stiffness was mentioned in the treatment of AS was evaluated! Predictor of response the administration of drugs constitutes an important component of the therapeutic programme in ankylosing spondylitis activity! Pain, stiffness and discomfort or delay more spinal problems and ease your pain and swelling in a 16‐week trial... Of efficacy gm daily in improving the symptoms of AS loss of mobility and function of. Characterized by sacroiliitis and spondylitis you to bend in different directions to the. Constitutes an important component of the clinical variables in patients with peripheral arthritis ( 1 ) in patient. Therapeutic programme in ankylosing spondylitis conventional treatments are palliative at best, the! 3 gm daily, using the double‐dummy method to aid in blinding tailored to your needs. © 2020 the Cochrane Collaboration months of treatment with sulfasalazine and the axial skeleton of sulfasalazine the... Early AS and in other joints it occurs most frequently in white males 20 to 40 years,! Approved the final version to be withdrawn from the ASCEND trial is tempered by certain aspects of the of.

Box Truck Camper Conversion, Murphy Brownes Killarney Menu, Hawaii Timeshare Presentation Deals 2020, Consultants In Gastroenterology Kansas City, All-clad D3 12-inch Fry Pan Canada,

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published.